Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2023年3月1日
	新闻
	Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789 Merck Lung cancer is the leading cause of cancer death worldwide. In 2020 alone, there were more than 2.2 million new cases and 1.8 million deaths from ... 标记为不相关
	NJ Health System Leverages AI, Robotics for Early Lung Cancer Diagnosis HealthITAnalytics The health system will leverage the Optellum Virtual Nodule Clinic within its early lung cancer diagnosis program at the Heart & Lung and Cancer ... 标记为不相关
	New life-saving tech uses robotics to help detect lung cancer - TODAY TODAY The center is one of the first on the West Coast to perform a robotic bronchoscopy, a critical step to detecting lung cancer before it's too late. 标记为不相关
	Merck's Keytruda fails more prostate and lung cancer PhIII trials - Endpoints News Endpoints News Merck's Keytruda fails more prostate and lung cancer PhIII trials. Kyle LaHucik. Associate Editor. Merck's cancer drug behemoth, the anti-PD1 Keytruda ... 标记为不相关
	RBM10 loss promotes EGFR-driven lung cancer and confers sensitivity to spliceosome inhibition AACR Journals In an EGFR-driven LUAD mouse model, lung-specific ablation of either Rbm10 or Trp53 similarly promoted tumor development, leading to overlapping ... 标记为不相关
	Merck ends last Keytruda study in aggressive prostate cancer bid - Fierce Pharma Fierce Pharma In Keytruda's home turf, non-small cell lung cancer, pairing the PD-1 inhibitor with chemotherapy didn't significantly prolong the lives of patients ... 标记为不相关
	Merck Keytruda combo fails lung cancer trial, sees another setback in prostate cancer Seeking Alpha Non-small cell lung cancer (NSCLC) trial: The phase 3 trial called KEYNOTE-789 was evaluating Keytruda in combination with pemetrexed (sold as ... 标记为不相关
	Register-Based Algorithm to identify Lung Cancer Recurrence | CLEP - Dove Medical Press Dove Medical Press Validating a register-based algorithm to identify patients diagnosed with recurrent lung cancer and to estimate the accuracy of the identified ... 标记为不相关
	FL-101 by Leap Therapeutics for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval Pharmaceutical Technology According to GlobalData, Phase I drugs for Squamous Non-Small Cell Lung Cancer have a 90% phase transition success rate (PTSR) indication ... 标记为不相关
	New life-saving tech uses robotics to help detect lung cancer - Yahoo News Yahoo News The center is one of the first on the West Coast to perform a robotic bronchoscopy, a critical step to detecting lung cancer before its too late. 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈